TrialThoracic cancer2024

A prospective single-center, single-arm, open-label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer.

Hongtao Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.